4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Hold at Wall Street Zen

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts also recently issued reports on the stock. Royal Bank Of Canada boosted their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday. Finally, Barclays began coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.71.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $8.61 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The stock has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $9.10. The company has a market cap of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. The firm had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. On average, research analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors have recently made changes to their positions in FDMT. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $41,000. Farther Finance Advisors LLC lifted its stake in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the period. Abich Financial Wealth Management LLC purchased a new stake in 4D Molecular Therapeutics in the third quarter worth $80,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at $77,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics News Roundup

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.